FIRST-IN-CLASS TRPM3 ANTAGONIST FOR NEUROPATHIC PAIN
BHV-2100 is Biohaven’s first-in-class molecule directed against TRPM3, a novel druggable target in the transient receptor potential (TRP) cation channel family.
TRPM3 is a Novel Druggable Target in the TRP Channel Family
